Anne-marie C. Fagan

Anne-marie C. Fagan's AcademicInfluence.com Rankings

Anne-marie C. Fagan

Biology

#7571

World Rank

#10513

Historical Rank

Neuroscience

#989

World Rank

#1030

Historical Rank

biology Degrees

Download Badge

Biology

Anne-marie C. Fagan's Degrees

PhD Neuroscience Stanford University

Why Is Anne-marie C. Fagan Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Anne-marie C. Fagan's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease (2011) (5616)
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. (2012) (2815)
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. (2015) (1112)
Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance (2011) (997)
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans (2006) (968)
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. (2007) (881)
Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. (2000) (869)
APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging (2010) (777)
Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction (2018) (758)
ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy (2017) (676)
Multimodal techniques for diagnosis and prognosis of Alzheimer's disease (2009) (631)
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup (2011) (624)
P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. (2005) (595)
Sleep quality and preclinical Alzheimer disease. (2013) (516)
APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline (2020) (507)
Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease (2016) (496)
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study (2013) (488)
Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease (2019) (487)
Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease (2019) (487)
Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. (2009) (470)
Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study (2012) (422)
YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease (2010) (393)
The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers (2011) (385)
Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. (2006) (370)
Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis (2017) (369)
Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease (2015) (365)
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis (2019) (360)
Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. (1999) (349)
White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network (2016) (341)
Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease (2014) (335)
GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer’s Disease (2013) (332)
Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer's disease (2006) (329)
Current state of Alzheimer’s fluid biomarkers (2018) (327)
Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model (2000) (324)
Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease (2009) (323)
Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease (2013) (318)
Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer disease: a longitudinal study (2018) (316)
Slow wave sleep disruption increases cerebrospinal fluid amyloid-&bgr; levels (2017) (288)
Functional connectivity and graph theory in preclinical Alzheimer's disease (2014) (288)
Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly (2009) (286)
Exercise and Alzheimer's disease biomarkers in cognitively normal older adults (2010) (263)
A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease (2020) (252)
Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status (2016) (252)
A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease (2020) (252)
Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition. (2012) (248)
Human and Murine ApoE Markedly Alters Aβ Metabolism before and after Plaque Formation in a Mouse Model of Alzheimer's Disease (2002) (242)
Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. (2015) (235)
Apolipoprotein E-containing High Density Lipoprotein Promotes Neurite Outgrowth and Is a Ligand for the Low Density Lipoprotein Receptor-related Protein* (1996) (230)
Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy. (2016) (228)
Suspected non-Alzheimer disease pathophysiology — concept and controversy (2016) (224)
Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. (2009) (217)
Multiplexed Immunoassay Panel Identifies Novel CSF Biomarkers for Alzheimer's Disease Diagnosis and Prognosis (2011) (214)
Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. (2009) (214)
Glial Fibrillary Acidic Protein–Apolipoprotein E (apoE) Transgenic Mice: Astrocyte-Specific Expression and Differing Biological Effects of Astrocyte-Secreted apoE3 and apoE4 Lipoproteins (1998) (212)
Unique Lipoproteins Secreted by Primary Astrocytes From Wild Type, apoE (−/−), and Human apoE Transgenic Mice* (1999) (210)
Reactive synaptogenesis assessed by synaptophysin immunoreactivity is associated with GAP-43 in the dentate gyrus of the adult rat (1991) (210)
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry (2017) (209)
Lipoproteins in the Central Nervous System (2000) (207)
Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later (2013) (206)
TrkA, But Not TrkC, Receptors Are Essential for Survival of Sympathetic Neurons In Vivo (1996) (206)
Early changes in CSF sTREM2 in dominantly inherited Alzheimer’s disease occur after amyloid deposition and neuronal injury (2016) (206)
Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research (2015) (205)
Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder (2008) (205)
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease (2012) (202)
Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. (2015) (201)
The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model (2017) (199)
Cholinergic sprouting in the hippocampus: A proposed role for IL-1 (1990) (195)
Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. (2012) (187)
Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. (2012) (186)
Fluid biomarkers in Alzheimer disease. (2012) (182)
Differential dependency of cutaneous mechanoreceptors on neurotrophins, trk receptors, and P75 LNGFR. (1997) (176)
Assessment of Racial Disparities in Biomarkers for Alzheimer Disease (2019) (173)
Non-TrkA-expressing small DRG neurons are lost in TrkA deficient mice (1995) (173)
Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease (2011) (172)
Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease (2009) (169)
Reduced non–rapid eye movement sleep is associated with tau pathology in early Alzheimer’s disease (2019) (168)
Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice (2001) (167)
Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging (2018) (166)
Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. (2011) (164)
Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease (2018) (163)
The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. (2016) (159)
CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease (2009) (158)
Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. (2015) (149)
Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease. (2016) (149)
Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer’s Disease (2016) (148)
Impaired default network functional connectivity in autosomal dominant Alzheimer disease (2013) (146)
A Role for TrkA during Maturation of Striatal and Basal Forebrain Cholinergic Neurons In Vivo (1997) (140)
Visinin‐like protein‐1: Diagnostic and prognostic biomarker in Alzheimer disease (2011) (140)
Severe Sensory Deficits but Normal CNS Development in Newborn Mice Lacking TrkB and TrkC Tyrosine Protein Kinase Receptors (1997) (137)
The utility of intraindividual variability in selective attention tasks as an early marker for Alzheimer's disease. (2009) (135)
Spatial Navigation in Preclinical Alzheimer's Disease. (2016) (133)
SNPs Associated with Cerebrospinal Fluid Phospho-Tau Levels Influence Rate of Decline in Alzheimer's Disease (2010) (128)
Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. (2013) (127)
Evidence for Normal Aging of the Septo-Hippocampal Cholinergic System in apoE (−/−) Mice but Impaired Clearance of Axonal Degeneration Products Following Injury (1998) (124)
Novel Role for Apolipoprotein E in the Central Nervous System (2003) (119)
Genome-wide association study identifies four novel loci associated with Alzheimer’s endophenotypes and disease modifiers (2017) (117)
Association of Cerebral Amyloid-&bgr; Aggregation With Cognitive Functioning in Persons Without Dementia (2018) (116)
Missense variant in TREML2 protects against Alzheimer's disease (2014) (115)
Differences in the Aβ40/Aβ42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype (2000) (115)
Genome-Wide Association Study of CSF Levels of 59 Alzheimer's Disease Candidate Proteins: Significant Associations with Proteins Involved in Amyloid Processing and Inflammation (2014) (114)
Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease. (2011) (113)
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease (2021) (113)
Biomarkers of Alzheimer's disease (2009) (112)
Plasma Cortisol and Progression of Dementia in DAT Subjects (2006) (110)
Grafting genetically modified cells into the rat brain: characteristics of E. coli beta-galactosidase as a reporter gene. (1989) (109)
Obstructive sleep apnea decreases central nervous system–derived proteins in the cerebrospinal fluid (2016) (108)
Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia (2003) (107)
Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. (2012) (106)
Functional connectivity in autosomal dominant and late-onset Alzheimer disease. (2014) (106)
Mechanisms of sprouting in the adult central nervous system: Cellular responses in areas of terminal degeneration and reinnervation in the rat hippocampus (1994) (106)
Associations between [18F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample (2017) (105)
Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer’s disease in a memory clinic cohort (2015) (105)
Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer’s disease (2018) (101)
Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition (2008) (94)
White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer’s disease (2018) (93)
Relationship of dementia screening tests with biomarkers of Alzheimer's disease. (2010) (93)
SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. (2013) (92)
Data-driven models of dominantly-inherited Alzheimer’s disease progression (2018) (89)
Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease (2016) (89)
Brain Imaging and Blood Biomarker Abnormalities in Children With Autosomal Dominant Alzheimer Disease: A Cross-Sectional Study. (2015) (89)
Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms (2018) (89)
Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology. (2016) (88)
NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers (2016) (88)
Endogenous FGF-2 Is Important for Cholinergic Sprouting in the Denervated Hippocampus (1997) (87)
Alzheimer’s disease risk variants show association with cerebrospinal fluid amyloid beta (2009) (87)
Cerebrospinal fluid Aβ42, phosphorylated Tau181, and resting-state functional connectivity. (2013) (87)
Comparative Proteomic Analysis of Intra- and Interindividual Variation in Human Cerebrospinal Fluid*S (2005) (87)
Extreme cerebrospinal fluid amyloid β levels identify family with late‐onset Alzheimer's disease presenilin 1 mutation (2007) (86)
Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-β (2005) (86)
Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease. (2015) (82)
Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels. (2016) (82)
Astrocyte lipoproteins, effects of apoE on neuronal function, and role of apoE in amyloid‐β deposition in vivo (2000) (79)
Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms (2007) (77)
Fine Mapping of Genetic Variants in BIN1, CLU, CR1 and PICALM for Association with Cerebrospinal Fluid Biomarkers for Alzheimer's Disease (2011) (75)
The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review (2018) (72)
A proteasomal stress response: pre‐treatment with proteasome inhibitors increases proteasome activity and reduces neuronal vulnerability to oxidative injury (2004) (71)
Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer’s disease (2018) (71)
Preclinical Alzheimer disease and risk of falls (2013) (71)
White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer’s disease (2018) (68)
11C-PiB imaging of human immunodeficiency virus-associated neurocognitive disorder. (2012) (67)
Biomarkers of Alzheimer's disease and mild cognitive impairment: a current perspective. (2015) (63)
ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis. (2004) (63)
The PSEN1, p.E318G Variant Increases the Risk of Alzheimer's Disease in APOE-ε4 Carriers (2013) (62)
Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease (2007) (62)
Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease (2019) (61)
Spatially distinct atrophy is linked to β-amyloid and tau in preclinical Alzheimer disease (2015) (61)
Factors associated with the onset and persistence of post-lumbar puncture headache. (2015) (60)
CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM2, neurodegeneration and cognitive decline (2018) (59)
BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. (2016) (59)
Intracerebral grafting of cultured autologous skin fibroblasts into the rat striatum: An assessment of graft size and ultrastructure (1991) (59)
Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: A Randomized Clinical Trial. (2019) (58)
Neurological manifestations of autosomal dominant familial Alzheimer’s disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS) (2016) (57)
Obstructive sleep apnea treatment, slow wave activity, and amyloid‐β (2019) (56)
Tau and Ab imaging, CSF measures, and cognition in Alzheimer’s disease (2016) (56)
Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease (2011) (56)
ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes (2019) (56)
Toward a multifactorial model of Alzheimer disease (2012) (55)
In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging (2017) (54)
Differences in the Abeta40/Abeta42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. (2000) (52)
Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease (2017) (52)
Cerebral amyloid-beta protein accumulation with aging in cotton-top tamarins: a model of early Alzheimer's disease? (2008) (51)
Cellular catabolism of lipid poor apolipoprotein E via cell surface LDL receptor-related protein. (2002) (50)
Role of family history for Alzheimer biomarker abnormalities in the adult children study. (2011) (49)
Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-beta. (2005) (49)
Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease (2017) (49)
Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels. (2010) (49)
Cognitively unimpaired HIV-positive subjects do not have increased 11C-PiB (2010) (48)
Quantitative Label-Free Proteomics for Discovery of Biomarkers in Cerebrospinal Fluid: Assessment of Technical and Inter-Individual Variation (2013) (48)
Unrecognized preclinical Alzheimer disease confounds rs-fcMRI studies of normal aging (2014) (48)
The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer’s disease (2019) (46)
Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease (2017) (46)
Certified normal: Alzheimer's disease biomarkers and normative estimates of cognitive functioning (2016) (45)
Alternative processing of γ‐secretase substrates in common forms of mild cognitive impairment and alzheimer's disease: Evidence for γ‐secretase dysfunction (2011) (44)
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. (2022) (44)
Relationship between Stroop performance and resting state functional connectivity in cognitively normal older adults. (2013) (43)
Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 years (2018) (42)
Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders (2021) (41)
Segregation of functional networks is associated with cognitive resilience in Alzheimer's disease. (2021) (41)
Lack of an association of BDNF Val66Met polymorphism and plasma BDNF with hippocampal volume and memory (2015) (40)
Sex-specific genetic predictors of Alzheimer’s disease biomarkers (2018) (40)
Vascular risk factors are associated with longitudinal changes in cerebrospinal fluid tau markers and cognition in preclinical Alzheimer's disease (2019) (40)
Cerebrospinal fluid biomarkers, education, brain volume, and future cognition. (2011) (39)
Neurodegenerative disease biomarkers Aβ1–40, Aβ1–42, tau, and p‐tau181 in the vervet monkey cerebrospinal fluid: Relation to normal aging, genetic influences, and cerebral amyloid angiopathy (2018) (39)
Nerve growth factor function in the central nervous system. (1991) (38)
Preclinical Alzheimer's disease and longitudinal driving decline (2016) (38)
Potential role of apoE in structural plasticity in the nervous system; implications for disorders of the central nervous system. (1998) (38)
The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer’s disease (2018) (38)
Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. (2018) (36)
Identifying amyloid pathology–related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study (2015) (36)
Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children Study (2016) (35)
Concordance of Lumipulse cerebrospinal fluid t‐tau/Aβ42 ratio with amyloid PET status (2020) (35)
Predicting sporadic Alzheimer’s disease progression via inherited Alzheimer’s disease-informed machine-learning (2020) (35)
Plasma Phospholipid and Sphingolipid Alterations in Presenilin1 Mutation Carriers: A Pilot Study. (2020) (34)
Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory (2018) (34)
Task-evoked fMRI changes in attention networks are associated with preclinical Alzheimer’s disease biomarkers (2015) (33)
Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network (2019) (33)
An 8-week, open-label, dose-finding study of nimodipine for the treatment of progranulin insufficiency from GRN gene mutations (2017) (32)
CSF biomarkers of Alzheimer disease (2013) (31)
A novel sensitive assay for detection of a biomarker of pericyte injury in cerebrospinal fluid (2020) (31)
Alzheimer Disease Cerebrospinal Fluid Biomarkers Moderate Baseline Differences and Predict Longitudinal Change in Attentional Control and Episodic Memory Composites in the Adult Children Study (2015) (31)
The Alzheimer's Biomarker Consortium‐Down Syndrome: Rationale and methodology (2020) (31)
Cortical Binding of Pittsburgh Compound B, an Endophenotype for Genetic Studies of Alzheimer's Disease (2010) (30)
Cerebrospinal Fluid Proteins Predict Longitudinal Hippocampal Degeneration in Early-stage Dementia of the Alzheimer Type (2012) (29)
Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study (2022) (29)
Progress Update: Fluid and Imaging Biomarkers in Alzheimer’s Disease (2014) (29)
Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance Among Cognitively Normal Individuals (2017) (29)
The search for antecedent biomarkers of Alzheimer's disease. (2006) (29)
High density lipoprotein decreases β‐amyloid toxicity in cortical cell culture (1997) (29)
Performance characteristics of plasma amyloid-beta 40 and 42 assays. (2009) (28)
Neurological Manifestations of Autosomal Dominant Alzheimer’s Disease from the DIAN cohort and a meta-analysis (2016) (27)
Alzheimer disease biomarkers, attentional control, and semantic memory retrieval: Synergistic and mediational effects of biomarkers on a sensitive cognitive measure in non-demented older adults. (2015) (27)
Cerebrospinal fluid biomarkers of Alzheimer's disease. (2010) (27)
Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease (2015) (26)
Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer’s disease (2016) (26)
GPS driving: a digital biomarker for preclinical Alzheimer disease (2021) (26)
No effect of apolipoprotein E on neuronal cell death due to excitotoxic and apoptotic agents in vitro and neonatal hypoxic ischaemia in vivo (2000) (26)
Effects of brain-derived neurotrophic factor and nerve growth factor on remaining neurons in the lesioned nucleus basalis magnocellularis (1994) (25)
Prospective Quantification of CSF Biomarkers in Antibody-Mediated Encephalitis (2021) (25)
Accelerated functional brain aging in pre-clinical familial Alzheimer’s disease (2021) (25)
Discovery and validation of autosomal dominant Alzheimer’s disease mutations (2018) (25)
Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers (2018) (24)
Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical AD (2015) (24)
Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light (2022) (23)
Parenchymal border macrophages regulate the flow dynamics of the cerebrospinal fluid (2022) (22)
Diurnal oscillation of CSF Aβ and other AD biomarkers (2017) (22)
Effect of escitalopram dose and treatment duration on CSF Aβ levels in healthy older adults (2020) (22)
Sequence of Alzheimer disease biomarker changes in cognitively normal adults (2020) (22)
Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's disease (2019) (22)
Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer’s disease (2018) (21)
Glial Fibrillary Acidic Protein – Apolipoprotein E ( apoE ) Transgenic Mice : Astrocyte-Specific Expression and Differing Biological Effects of Astrocyte-Secreted apoE 3 and apoE 4 Lipoproteins (1998) (21)
Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease (2018) (21)
Effect of simvastatin on CSF Alzheimer disease biomarkers in cognitively normal adults (2017) (21)
Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease (2019) (20)
Proximity to Parental Symptom Onset and Amyloid-&bgr; Burden in Sporadic Alzheimer Disease (2018) (19)
Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease (2020) (18)
Spatial navigation ability predicts progression of dementia symptomatology (2020) (18)
Fluid Biomarkers for Alzheimer’s Disease (2013) (18)
Staging biomarkers in preclinical autosomal dominant Alzheimer's disease by estimated years to symptom onset (2019) (18)
African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants (2021) (18)
Amyloid imaging of dutch‐type hereditary cerebral amyloid angiopathy carriers (2019) (17)
Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study (2022) (17)
CSF Biomarkers of Alzheimer’s Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design (2014) (17)
Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study (2021) (17)
The Longitudinal Early‐onset Alzheimer's Disease Study (LEADS): Framework and methodology (2021) (16)
Functional connectivity among brain regions affected in Alzheimer’s disease is associated with CSF TNF-α in APOE4 carriers (2019) (16)
Erratum to “Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial” [Rev. Neurol. 169 (10) (2013) 737–743] (2013) (16)
Missense variant in TREML 2 protects against Alzheimer ’ s Disease (2013) (15)
Bivariate correlation coefficients in family‐type clustered studies (2015) (14)
Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome (2020) (14)
The Relation Between Personality and Biomarkers in Sensitivity and Conversion to Alzheimer-Type Dementia (2019) (14)
Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40 (2016) (13)
A novel PSEN1 mutation (I238M) associated with early-onset Alzheimer's disease in an African-American woman. (2014) (13)
Multiple γ-secretase product peptides are coordinately increased in concentration in the cerebrospinal fluid of a subpopulation of sporadic Alzheimer’s disease subjects (2012) (13)
Sharper in the morning: Cognitive time of day effects revealed with high-frequency smartphone testing (2021) (12)
Predicting brain age from functional connectivity in symptomatic and preclinical Alzheimer disease (2022) (12)
Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET (2021) (12)
Examination of the Effect of Rare Variants in TREM2, ABI3, and PLCG2 in LOAD Through Multiple Phenotypes. (2020) (12)
Alzheimer Disease Biomarkers and Driving in Clinically Normal Older Adults: Role of Spatial Navigation Abilities (2018) (12)
Resting State Functional Connectivity Signature Differentiates Cognitively Normal from Individuals Who Convert to Symptomatic Alzheimer's Disease. (2020) (12)
Evaluating resting-state BOLD variability in relation to biomarkers of preclinical Alzheimer's disease (2020) (11)
Modeling autosomal dominant Alzheimer's disease with machine learning (2021) (11)
Decreased platelet APP isoform ratios in autosomal dominant Alzheimer's disease: baseline data from a DIAN cohort subset. (2015) (11)
Examining the Complicated Relationship Between Depressive Symptoms and Cognitive Impairment in Preclinical Alzheimer Disease (2019) (11)
Temporal Correlation of CSF and Neuroimaging in the Amyloid-Tau-Neurodegeneration Model of Alzheimer Disease (2021) (11)
Neuropsychiatric Symptoms and Alzheimer's Disease Biomarkers Predict Driving Decline: Brief Report. (2017) (10)
Blood–brain barrier breakdown is an early biomarker of human cognitive dysfunction (2019) (10)
Alzheimer Research Forum live discussion: insulin resistance: a common axis linking Alzheimer's, depression, and metabolism? (2006) (10)
Developing a Spatial Navigation Screening Tool Sensitive to the Preclinical Alzheimer Disease Continuum. (2019) (10)
Neurofilament Light Predicts Decline in Attention but Not Episodic Memory in Preclinical Alzheimer's Disease. (2020) (10)
Genomic and multi-tissue proteomic integration for understanding the biology of disease and other complex traits (2020) (10)
Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease (2021) (9)
Correspondence of CSF biomarkers measured by Lumipulse assays with amyloid PET (2021) (9)
Physical Exercise and Longitudinal Trajectories in Alzheimer Disease Biomarkers and Cognitive Functioning (2020) (9)
High density lipoprotein decreases beta-amyloid toxicity in cortical cell culture. (1997) (9)
Differential Cued-Stroop Performance in Cognitively Asymptomatic Older Adults with Biomarker-Identified Risk for Alzheimer's Disease: A Pilot Study. (2018) (9)
Remote cognitive assessment approaches in the Dominantly Inherited Alzheimer Network (DIAN) (2020) (9)
Driving cessation over a 24-year period: Dementia severity and cerebrospinal fluid biomarkers (2018) (9)
Identifying Preclinical Alzheimer's Disease Using Everyday Driving Behavior: Proof of Concept. (2020) (8)
Cerebrospinal fluid biomarkers, education, brain volume and future cognition (2011) (8)
Relationships between big‐five personality factors and Alzheimer's disease pathology in autosomal dominant Alzheimer's disease (2020) (8)
Cerebrospinal Fluid Biomarkers and Reserve Variables as Predictors of Future "Non-Cognitive" Outcomes of Alzheimer's Disease. (2016) (8)
Depression and Alzheimer's Disease Biomarkers Predict Driving Decline. (2018) (8)
Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease (2018) (7)
Process Dissociation Analyses of Memory Changes in Healthy Aging, Preclinical, and Very Mild Alzheimer Disease: Evidence for Isolated Recollection Deficits (2017) (7)
Quantitative Gradient Echo MRI Identifies Dark Matter as a New Imaging Biomarker of Neurodegeneration that Precedes Tissue Atrophy in Early Alzheimer’s Disease (2021) (7)
Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN) (2020) (7)
A harmonized longitudinal biomarkers and cognition database for assessing the natural history of preclinical Alzheimer's disease from young adulthood and for designing prevention trials (2019) (6)
Comparative Analysis of Alzheimer's Disease Cerebrospinal Fluid Biomarkers Measurement by Multiplex SOMAscan Platform and Immunoassay-Based Approach. (2022) (6)
THE DOMINANTLY INHERITED ALZHEIMER NETWORK TRIALS UNIT (2016) (6)
Association of BDNF Val66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease. (2022) (6)
Carcinoma of the oesophagus and cardia (1977) (6)
Preclinical Alzheimer's disease criteria (2013) (6)
Clinical and Paraclinical Measures Associated with Outcome in Cerebral Amyloid Angiopathy with Related Inflammation. (2021) (6)
Alzheimer's disease biomarker states (2016) (6)
Cerebrospinal fluid neurofilament light chain is a marker of aging and white matter damage (2022) (6)
Cognitively normal APOE ε4 carriers have specific elevation of CSF SNAP-25 (2020) (6)
Baseline Microglial Activation Correlates With Brain Amyloidosis and Longitudinal Cognitive Decline in Alzheimer Disease (2022) (6)
Autosomal dominant and sporadic late onset Alzheimer disease share a common in vivo pathophysiology. (2022) (6)
Presymptomatic Alzheimer's disease in the Dominantly Inherited Alzheimer's Network (DIAN) (2012) (5)
Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders (2022) (5)
A Phase II Study Repurposing Atomoxetine for Neuroprotection in Mild Cognitive Impairment (2021) (5)
Network dysfunction in cognitively normal APOE ε4 carriers is related to subclinical tau (2021) (5)
Cerebrospinal fluid Aβ42 moderates the relationship between brain functional network dynamics and cognitive intraindividual variability (2020) (5)
What does it mean to be 'amyloid-positive'? (2015) (5)
COMPARING SMARTPHONE-ADMINISTERED COGNITIVE ASSESSMENTS WITH CONVENTIONAL TESTS AND BIOMARKERS IN SPORADIC AND DOMINANTLY INHERITED ALZHEIMER DISEASE (2018) (5)
Plasma Amyloid-Beta Levels in a Pre-Symptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy Pedigree: A Cross-Sectional and Longitudinal Investigation (2021) (5)
CLINICAL PERFORMANCE OF NEUROGRANIN AS A CEREBROSPINAL FLUID BIOMARKER FOR ALZHEIMER’S DISEASE: AN ASSAY COMPARISON STUDY (2017) (4)
Racial differences in longitudinal Alzheimer's disease biomarkers among cognitively normal adults (2022) (4)
A novel PSEN1 (S230N) mutation causing early-onset Alzheimer’s Disease associated with prosopagnosia, hoarding, and Parkinsonism (2017) (4)
Using the A/T/N Framework to Examine Driving in Preclinical Alzheimer’s Disease (2018) (4)
Mass spectrometry measures of plasma Aβ, tau and P‐tau isoforms’ relationship to amyloid PET, tau PET, and clinical stage of Alzheimer’s disease (2020) (4)
Overview of dominantly inherited AD and top‐line DIAN‐TU results of solanezumab and gantenerumab (2020) (4)
Gantenerumab in‐depth outcomes: Results of the DIAN‐TU prevention trial of solanezumab and gantenerumab in dominantly inherited AD (2020) (4)
Presymptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy-Related Blood Metabolite Alterations. (2020) (4)
RESTING-STATE FUNCTIONAL CONNECTIVITY IS ASSOCIATED WITH PATHOLOGICAL BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE (2018) (4)
Adverse driving behaviors are associated with sleep apnea severity and age in cognitively normal older adults at risk for Alzheimer's disease. (2022) (4)
Alternative Processing of c-Secretase Substrates in Common Forms of Mild Cognitive Impairment and Alzheimer’s Disease: Evidence for c-Secretase Dysfunction (2011) (3)
Preclinical Alzheimer's disease biomarkers accurately predict cognitive and neuropathological outcomes. (2022) (3)
Task-switching errors show sensitivity to preclinical Alzheimer's disease biomarkers (2015) (3)
Ptau-Aβ42 ratio as a continuous trait for biomarker discovery for early stage Alzheimer’s disease in multiplex immunoassay panels of Cerebrospinal fluid (2014) (3)
USING THE A/T/N FRAMEWORK TO EXAMINE DRIVING IN PRECLINICAL AD (2018) (3)
Amyloid imaging and cerebrospinal fluid biomarkers predict driving performance in preclinical Alzheimer's disease (2015) (3)
Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-B $ (2005) (3)
Falls: a marker of preclinical Alzheimer disease: a cohort study protocol (2021) (3)
Alzheimer's Disease Longitudinal Change in CSF Biomarkers in Autosomal-Dominant (2014) (3)
LONGITUDINAL CHANGES IN FUNCTIONAL CONNECTIVITY IN CONVERSION TO SYMPTOMATIC AD (2019) (3)
Diffusion tensor imaging detected neurodegeneration in preclinical Alzheimer disease (2015) (2)
ESCITALOPRAM DECREASES LONGITUDINAL CSF ABETA CONCENTRATION IN COGNITIVELY NORMAL SUBJECTS AGE 60-85 (2016) (2)
An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations (2019) (2)
Accelerated longitudinal changes and ordering of Alzheimer disease biomarkers across the adult lifespan. (2022) (2)
Sex‐associated differences in pathology burden in early‐onset Alzheimer’s disease (2020) (2)
Diffusion tensor imaging detected neurodegeneration in preclinical Alzheimer disease (2015) (2)
Multi-tissue proteomics identifies molecular signatures for sporadic and genetically defined Alzheimer disease cases (2021) (2)
UPWARD DRIFT IN CSF AB42 VALUES OVER 10 YEARS (2016) (2)
Gantenerumab in‐depth outcomes (2020) (2)
Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk (2021) (2)
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study (2023) (2)
A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment. (2021) (2)
Unsupervised high-frequency smartphone-based cognitive assessments are reliable, valid, and feasible in older adults at risk for Alzheimer's disease. (2022) (2)
MORE POWERFUL STATISTICAL APPROACHES FOR LONGITUDINAL COMPARISONS OF AD SUBTYPES ON CSF AND IMAGING BIOMARKERS FROM DOMINANTLY INHERITED ALZHEIMER NETWORK (DIAN) AND ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI) (2018) (2)
Tau positron emission tomography imaging in C9orf72 repeat expansion carriers (2019) (2)
MASS SPECTROMETRY–BASED MEASUREMENT OF LONGITUDINAL CSF TAU IDENTIFIES DIFFERENT PHOSPHORYLATED SITES THAT TRACK DISTINCT STAGES OF PRESYMPTOMATIC DOMINANTLY INHERITED AD (2018) (2)
Plasma and cerebrospinal fluid markers in the DIAN study of autosomal-dominant Alzheimer's disease (2011) (2)
Review Article Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease (2014) (2)
Sharper in the morning: Cognitive sundowning revealed with high‐frequency smartphone testing (2021) (2)
IMPAIRED DEFAULT NETWORK FUNCTIONAL CONNECTIVITY IN DIAN (2014) (2)
Different rates of cognitive decline in autosomal dominant and late‐onset Alzheimer disease (2021) (2)
Multimodal brain age estimates relate to Alzheimer disease biomarkers and cognition in early stages: a cross-sectional observational study (2022) (2)
RACIAL DIFFERENCES AND SIMILARITIES IN MOLECULAR BIOMARKERS FOR AD (2017) (2)
Elevated PiB precedes dementia in autosomal dominant Alzheimer's disease: PiB, FDG and atrophy in the DIAN cohort (2012) (2)
LONGITUDINAL BIOMARKER CHANGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE FROM THE DIAN STUDY (2017) (2)
Undetected Neurodegenerative Disease Biases Estimates of Cognitive Change in Older Adults (2021) (2)
IN VIVO TAU IMAGING BY POSITRON EMISSION TOMOGRAPHY IN PATIENTS WITH C9ORF72 HEXANUCLEOTIDE REPEAT EXPANSIONS (2017) (1)
Brain network decoupling with increased serum neurofilament and reduced cognitive function in Alzheimer's disease. (2023) (1)
Comparison of plasma and CSF biomarkers in predicting cognitive decline (2022) (1)
CEREBROSPINAL FLUID LEVELS OF AMYLOID BETA AND TAU AS ENDOPHENOTYPES REVEAL NOVEL VARIANTS POTENTIALLY INFORMATIVE FOR ALZHEIMER'S DISEASE (2016) (1)
Identifying preclinical Alzheimer disease from driving patterns: A machine learning approach (2021) (1)
Progressive white matter abnormalities in autosomal dominant Alzheimer's disease: Results of the DIAN study (2012) (1)
Prevalence and growth of cerebral microhemorrhages in autosomal dominant Alzheimer's disease (2013) (1)
Diurnal oscillation of CSF Aβ and other AD biomarkers (2017) (1)
Sleep Disruption and Risk of Preclinical Alzheimer Disease (P01.081) (2012) (1)
Amyloid and tau PET in sporadic early‐onset Alzheimer’s disease: Preliminary results from LEADS (2020) (1)
Aging, biomarkers and behavior in Caribbean vervets (2010) (1)
EMERGING CSF BIOMARKERS OF NEUROINFLAMMATION, NEURONAL INJURY AND SYNAPTIC INTEGRITY IN THE ADNI COHORT (2016) (1)
REGIONAL VARIABILITY OF IMAGING BIOMARKERS IN DIAN (2014) (1)
Functions of NGF on Central Cholinergic Neurons (1990) (1)
CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease (2022) (1)
Working Mothers ’ Contributions to Family Income : Proportions and Effects (2009) (1)
ALZHEIMER DISEASE BIOMARKERS PREDICT DIFFERENCES IN PERSONALITY: A CROSS-LAGGED PANEL ANALYSIS (2018) (1)
Relationships between baseline biomarkers and subsequent cognitive decline in cognitively unimpaired PSEN1 E280A mutation carriers from the colombian kindred with autosomal dominant Alzheimer’s disease (2015) (1)
DRIVING CESSATION OVER A 22-YEAR PERIOD: DEMENTIA SEVERITY AND CSF BIOMARKERS (2017) (1)
Disrupted functional connectivity in autosomal dominant Alzheimer's disease: Preliminary findings from the DIAN study (2012) (1)
Elevated cerebrospinal fluid amyloid-Beta42 levels in young adults at genetic risk for early-onset alzheimer's disease (2011) (1)
Patterns of tau binding in T807-PET imaging (2015) (1)
THE DOMINANTLY INHERITED ALZHEIMER NETWORK (DIAN)-ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE (ADNI) COMPARISON STUDY: CHALLENGES AND OPPORTUNITIES (2018) (1)
Are early atrophy patterns in autosomal dominant familial Alzheimer's disease gene-dependent? (2013) (1)
Pattern and implications of neurological examination findings in autosomal dominant Alzheimer disease (2022) (1)
P3-232: SNPs in SOAT1, TFAM, and CNDP1 are associated with cerebrospinal fluid amyloid-beta levels (2008) (1)
Polygenic Risk Score of Sporadic late Onset Alzheimer Disease Reveals a Shared Architecture with the Familial and Early Onset Forms (2017) (1)
Resting state functional connectivity in autosomal dominant and sporadic Alzheimer’s disease (2013) (1)
BLOOD AMYLOID-BETA PREDICTS AMYLOID PET CONVERSION (2019) (1)
Mendelian randomization and genetic colocalization infer the effects of the multi-tissue proteome on 211 complex disease-related phenotypes (2022) (1)
Proteomic clusters underlie heterogeneity in preclinical Alzheimer's disease progression. (2022) (1)
How do we define amyloid positivity in an asymptomatic population? Comparison of CSF, quantitative PET and clinical PET examinations (2013) (1)
Blood-based biomarkers of Alzheimer’s disease: Lessons to be learned from studies of cerebrospinal fluid markers (2013) (1)
Relationship between brain A{beta} deposition and CSF A{beta}42 several years prior to amyloid positivity (2014) (1)
Multiple γ-secretase product peptides are coordinately increased in concentration in the cerebrospinal fluid of a subpopulation of sporadic Alzheimer’s disease subjects (2012) (1)
IMAGING MARKER OF NEUROINFLAMMATION PREDICTS PROGRESSION IN ALZHEIMER'S DISEASE (2016) (1)
LONGITUDINAL CHANGE IN CSF BIOMARKERS IN DIAN (2014) (1)
Evaluation of dose‐dependent treatment effects after mid‐trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease (2022) (1)
Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer’s disease in a memory clinic cohort (2015) (1)
Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer's disease: Associations with Aβ-PET, neurodegeneration, and cognition. (2022) (1)
Detecting preclinical markers of dementia: The power of sustained attention and mind-wandering (2012) (1)
Resting State Functional Connectivity Signature Differentiates Cognitively Normal from Individuals Who Convert to Symptomatic Alzheimer Disease (2020) (1)
Plasma Neurofilament Light Chain Levels Are Elevated in Children and Young Adults With Wolfram Syndrome (2022) (1)
BRAIN AEROBIC GLYCOLYSIS AND AD PATHOLOGY BIOMARKERS IN AUTOSOMAL DOMINANT AD (2017) (1)
Age-associated trajectories of biomarkers in early-onset Alzheimer's disease, for the Alzheimer's Prevention Initiative (2012) (1)
White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantlyinherited Alzheimer’s disease (2018) (1)
Review Article Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research (2014) (1)
Solanezumab in‐depth outcomes (2020) (1)
Prevalence and growth of cerebral microhemorrhages in autosomal dominant Alzheimer's disease (2013) (1)
NCMP-24. PRE-INFUSION NEUROFILAMENT LIGHT CHAIN (NFL) LEVELS PREDICT THE DEVELOPMENT OF IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME (ICANS) (2020) (1)
Performance of a Non-Invasive Blood Test for a Conformational Variant of p53 to Predict Alzheimer’s Disease Within 6 Years of Clinical Diagnosis (2021) (1)
IMPACT OF COGNITIVE RESERVE AND PRECLINICAL AD ON LONGITUDINAL DRIVING PERFORMANCE (2017) (1)
Longitudinal increase of CSF soluble TREM2 is driven by early aggregation of Aβ42 and associates with slower amyloid deposition and clinical decline in autosomal-dominant Alzheimer’s disease (2021) (1)
Resting state functional connectivity in autosomal dominant and sporadic Alzheimer's disease (2013) (1)
The Novel Neuronal Injury Marker, Visinin-like Protein-1 (VILIP-1), as a Diagnostic and Prognostic Marker in Alzheimer's Disease (2010) (0)
FUNCTIONAL ARCHITECTURAL DIFFERENCES BETWEEN AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE AND LATE ONSET ALZHEIMER’S DISEASE (2018) (0)
Brain Biomarkers: Follow-Up of RNA Expression Discovery Approach: CSF Assays for Neurogranin, SNAP-25, and VILIP-1 (2021) (0)
NEUROPSYCHIATRIC SYMPTOMS AND ALZHEIMER DISEASE BIOMARKERS PREDICT DRIVING DECLINE (2017) (0)
PHOSPHORYLATION OF SPECIFIC TAU SITES IS ASSOCIATED WITH LOSS OF WHITE MATTER INTEGRITY IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE (2019) (0)
CSF INTERLEUKIN-8, A KEY SIGNALING FACTOR FOR INFLAMMATION, IS ASSOCIATED WITH FUNCTIONAL CONNECTIVITY AND EXECUTIVE FUNCTION (2019) (0)
A novel MRI approach for evaluation of microstructural neurodegeneration in early Alzheimer disease (2021) (0)
Pooling CSF Measurements Across Multiple Cohorts in the Preclinical Alzheimer's Consortium (2022) (0)
CSF non-Beta-Amyloid, non-Tau Biomarkers for Clinical Alzheimer’s Disease Stages (S48.002) (2018) (0)
A voxel-based morphometry study of volumetric MRI in familial Alzheimer's disease (2012) (0)
Presence of co‐pathology in sporadic early‐onset Alzheimer disease versus dominantly inherited Alzheimer disease (2021) (0)
Gamma-secretase dysfunction in sporadic Alzhemer's disease suggested by p3-Alc peptide, metabolic product of Alcadein (2010) (0)
CSF VILIP-1 AND YKL-40, NOVEL CANDIDATE BIOMARKERS TO DIAGNOSE, PREDICT, AND MONITOR ALZHEIMER'S DISEASE (2014) (0)
PREDICTION OF INCIDENT DEMENTIA: LONGITUDINAL BIOMARKER AND CLINICAL CHANGES BEFORE AND AFTER (2017) (0)
PROSPECTIVE ESCITALOPRAM DECREASES LONGITUDINAL CSF Aβ CONCENTRATION IN COGNITIVELY NORMAL ELDERLY SUBJECTS: A RANDOMIZED DOSE FINDING STUDY (2017) (0)
EARLY RESTING-STATE NETWORK DYSFUNCTION IN APOE ε4 CARRIERS WITHOUT BIOMARKER EVIDENCE OF ALZHEIMER’S DISEASE IS RELATED TO SUBCLINICAL TAU CHANGES (2019) (0)
Cross-Sectional and Longitudinal Comparisons of Biomarkers and Cognition Among Asymptomatic Middle-Aged Individuals with a Parental History of Either Autosomal Dominant or Late Onset Alzheimer Disease (2021) (0)
Schindler Supplemental Materials (2019) (0)
Novel CSF biomarkers of synaptic dysfunction (2015) (0)
Longitudinal biomarker connectivity on middle-aged asymptomatic individuals and optimal design on prevention trials of Alzheimer's disease (2015) (0)
A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease (2020) (0)
A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease (2020) (0)
CSF and blood plasma mass spectrometry measures of Aβ, tau, and NfL species and longitudinal relationship to preclinical and clinical staging of amyloid and tau aggregation and clinical stage of Alzheimer’s disease (2021) (0)
P4-127 EXPLORING THE UTILITY OF CSF NEUROGRANIN LEVELS IN AN ALZHEIMER’S DISEASE CLINICALTRIAL (2016) (0)
Sample size estimation for clinical trials with tau‐PET SUVR as the primary outcome in dominantly inherited Alzheimer’s disease (2021) (0)
IC-P-054 Relationship between in vivo amyloid imaging with 11C-PIB and CSF Aβ42 (2006) (0)
CSF biomarkers of antecedent Alzheimer's disease (2010) (0)
Gantnerumab In-depth Outcomes (2020) (0)
The impact of pre-analytical variables on measuring CSF biomarkers for Alzheimer’s disease diagnosis: A review (2019) (0)
Plasma Aβ42/Aβ40 ratios are not reduced in older people living with HIV. (2023) (0)
Diagnostic utility of CSF biomarkers in an Alzheimer's clinic (2011) (0)
NEURONAL INJURY AND DEGENERATION EVALUATED WITH IMAGING AND CSF BIOMARKERS IN AUTOSOMAL DOMINANT AD: RESULTS FROM THE DIAN STUDY (2016) (0)
FROM THE ALZHEIMER ’ S ASSOCIATION INTERNATIONAL CONFERENCE 2017 ALZHEIMER ’ S ASSOCIATION LAUNCHES $ 20 MILLION LIFESTYLE INTERVENTION TRIAL IN THE U . S . TO PREVENT COGNITIVE DECLINE – (2017) (0)
Modeling functional and structural brain‐predicted age in relation to Alzheimer disease and cognition (2022) (0)
IC-01-01: Cortical binding of Pittsburgh compound B, an endophenotype for genetic studies of Alzheimer's disease (2008) (0)
Plasma and Cerebrospinal Fluid Markers in the DIAN Study of Autosomal-Dominant Alzheimer’s Disease (2011) (0)
Comparison of nia-aa preclinical Alzheimer's disease staging with CSF and neuroimaging biomarkers (2015) (0)
UTILITY OF PERFUSION PET MODELS AS MEASURES OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE POPULATION: REPORT FROM THE DIAN STUDY (2017) (0)
A novel diagnostic and prognostic fluid biomarker for early Alzheimer's disease: YKL-40 (2010) (0)
ELEVATED CSF STREM2 IN AUTOSOMAL DOMINANTLY INHERITED ALZHEIMER’S DISEASE ASSOCIATED WITH REGIONAL FIBER TRACT INJURY: RESULTS FROM THE DIAN STUDY (2017) (0)
3-12-15 ApoE isoforms do not modify neuronal susceptibility to injury by certain excitotoxic or apoptotic agents in cortical cell culture (1997) (0)
QUANTIFICATION OF WHITE MATTER CELLULARITY IN PRECLINICAL AND EARLY SYMPTOMATIC ALZHEIMER DISEASE USING NEURO-IMMNUE IMAGING (2018) (0)
CSF LEVELS OF STREM2 ARE ASSOCIATED WITH GREATER FRONTAL CORTICAL THICKNESS DURING ADVANCED DISEASE STAGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE (2016) (0)
Raindrop animation: Visualizing change in longitudinal biomarker data (2022) (0)
Identifying multi-analyte CSF biomarkers for Alzheimer’s disease in a multi-cohort study (2013) (0)
EXPLORING THE UTILITY OF CSF NEUROGRANIN LEVELS IN AN ALZHEIMER’S DISEASE CLINICAL TRIAL (2016) (0)
DYNAMIC RELATIONSHIPS BETWEEN “BIG FIVE” PERSONALITY TRAITS, ALZHEIMER’S DISEASE BIOMARKERS, AND COGNITION IN AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE (2016) (0)
DIFFERENTIAL EFFECT OF PROSPECTIVE ESCITALOPRAM DECREASE ON LONGITUDINAL CSF AB CONCENTRATION IN AMYLOID (+) VERSUS AMYLOID (-) COGNITIVELY NORMAL ELDERLY INDIVIDUALS (2018) (0)
Alzheimer's disease biomarkers and normative cognitive data: The SuperNorms approach (2013) (0)
Increased white matter MRI T1 hypointensity volume in young‐onset Alzheimer’s disease patients is not accounted for by age or cardiovascular risk factors (2020) (0)
PLASMA Aβ42/Aβ40 PREDICTS HIPPOCAMPAL ATROPHY (2019) (0)
CONCENTRATIONS AND STABLE ISOTOPE LABEL KINETICS OF HUMAN PLASMA AMYLOID BETA (2017) (0)
CONCORDANCE BETWEEN IN VIVO AMYLOID IMAGING AND CSF AB1-42 AND TOTAL TAU MEASURED BY THE AUTOMATED LUMIPULSE® G ASSAY PLATFORM (2018) (0)
CSF SPDGFRB, A MEASURE OF VASCULAR DYSFUNCTION, IS RELATED TO DISRUPTED FUNCTIONAL CONNECTIVITY AMONG BRAIN REGIONS ASSOCIATED WITH ALZHEIMER’S DISEASE (2018) (0)
PRECLINICAL ALZHEIMER’S DISEASE PREDICTS LONGITUDINAL ONSET OF DRIVING DIFFICULTIES AMONG COGNITIVELY NORMAL PERSONS (2016) (0)
LONGITUDINAL CLINICAL AND BIOMARKER CHANGES IN DOMINANTLY INHERITED ALZHEIMER'S DISEASE: THE DOMINANTLY INHERITED ALZHEIMER NETWORK (2016) (0)
Identification and validation of novel cerebrospinal fluid protein biomarkers for early Alzheimer's disease using proteomics and ELISA: a multi-institutional collaborative study (2010) (0)
Lack of an association of BDNF Val66Met polymorphism and plasma BDNF with hippocampal volume and memory (2015) (0)
LONGITUDINAL CHANGES IN CEREBROSPINAL FLUID BIOMARKERS OF ALZHEIMER'S DISEASE: FINDINGS FROM A COGNITIVELY NORMAL, MIDDLE-AGED COHORT (2014) (0)
FUNCTIONAL ARCHITECTURAL DIFFERENCES BETWEEN AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE AND LATE ONSET ALZHEIMER’S DISEASE (2018) (0)
REGIONAL PIB DEPOSITION AND CSF Aβ42 LEVELS SEVERAL YEARS PRIOR TO AMYLOID POSITIVITY (2014) (0)
EMERGING CSF BIOMARKERS AS PREDICTORS OF ALZHEIMER DISEASE DEMENTIA (2017) (0)
Cross‐modal associations between traditional and emerging CSF biomarkers and grey matter network disruption in autosomal dominant Alzheimer disease (2020) (0)
Sex and APOE‐ε4 carrier effects on early‐onset Alzheimer’s disease pathology (2022) (0)
NEURONAL INJURY AND DEGENERATION EVALUATED WITH IMAGING AND CSF BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: RESULTS FROM THE DIAN STUDY (2016) (0)
Using cerebrospinal fluid markers to identify stages of National Institute on Aging and Alzheimer’s Association proposed criteria for preclinical Alzheimer's disease and its prognosis (2013) (0)
Dissociating volume and intensity differences in familial Alzheimer's disease (2013) (0)
Plasma multianalyte profiling of mild cognitive impairment and Alzheimer's disease in two academic centers and the Alzheimer's Disease Neuroimaging Initiative (2011) (0)
Title ( 82 / 100 characters ) : Neurogranin as cerebrospinal fluid biomarker for dementia-assay comparison study (2018) (0)
The role of nerve growth factor family receptors in the development of the mammalian nervous system (1994) (0)
Imaging measures of molecular pathology and neurodegeneration in dominantly‐inherited and sporadic early‐onset Alzheimer’s Disease (2021) (0)
HABITUAL EXERCISE LEVELS ARE ASSOCIATED WITH CEREBRAL AMYLOID LOAD IN PRE-SYMPTOMATIC AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE (2017) (0)
Neurodegeneration in the Longitudinal Evaluation of Early Onset Alzheimer’s Disease Study (LEADS) sample: Results from the MRI core (2020) (0)
p3-Alc peptides produced by covariant processing of Alcadein and APP implicate γ-secretase dysfunction in sporadic Alzheimer's disease (2009) (0)
YEARS TO PARENTAL SYMPTOM ONSET PREDICTS AMYLOID BURDEN IN HEALTHY ELDERLY WITH A PARENTAL HISTORY OF SPORADIC ALZHEIMER DISEASE (2017) (0)
P3-095: Levels of CSF biomarkers predict rate of cognitive decline in individuals with very mild dementia of the Alzheimer's type (2008) (0)
SIMULTANEOUS QUANTIFICATION OF WHITE MATTER ABNORMALITIES AND VASOGENIC EDEMA IN EARLY ALZHEIMER DISEASE (2016) (0)
Comparing neuroimaging and cerebrospinal fluid markers of amyloid, tau, and neurodegenerative biomarkers: implications for understanding the biology of the disease (2022) (0)
LONGITUDINAL COURSE OF PRECLINICAL AD USING THE A/T/N FRAMEWORK (2018) (0)
Amyloid‐Related Imaging Abnormalities in the DIAN‐TU‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease (2022) (0)
Role of APOE in Alzheimer's disease-like neurodegeneration (2000) (0)
ADVANCING CLINICAL AND BIOMARKER RESEARCH IN AD: THE LEAD STUDY (2019) (0)
Interactive effects of a sedentary lifestyle and the APOE e4 allele on amyloid deposition (2011) (0)
O3-02-02: Update on the relationship between in vivo amyloid imaging with C-PIB and CSF Aβ42 (2008) (0)
Comparison of amyloid accumulation between Down syndrome and autosomal‐dominant Alzheimer disease (2022) (0)
BRAIN AEROBIC GLYCOLYSIS AND AD PATHOLOGY BIOMARKERS IN AUTOSOMAL DOMINANT AD (2017) (0)
AD‐causing variants that affect PSEN1 transmembrane domains are associated with faster neurodegeneration and cognitive decline compared to those affecting cytoplasmic domains (2022) (0)
THE EMERGING CEREBROSPINAL FLUID BIOMARKER SNAP-25 IS ELEVATED IN APOEε4 CARRIERS IN COGNITIVELY NORMAL INDIVIDUALS (2006) (0)
QUANTIFYING PRECLINICAL STAGES OF AUTOSOMAL DOMINANT ALZHEIMER DISEASE (ADAD) AND THE ASSOCIATED OVERALL BIOMARKER SIGNATURE ACROSS MODALITIES USING THE DOMINANTLY INHERITED ALZHEIMER NETWORK (DIAN) (2017) (0)
Medication Use as a Confounding Factor in the Use of the Cerebrospinal Fluid tau/β-Amyloid42 Ratio—Reply (2007) (0)
Lower body mass index is associated with greater Alzheimer pathology in asymptomatic individuals (2015) (0)
Patterns of tau binding in T807-PET imaging (2015) (0)
P2-294: Microarray profiling reveals autoantibody reactivities against abnormal amyloid peptide conformations decline with age and in Alzheimer's disease (2008) (0)
SORTOUT‐AB: A Study of Race to Understand Alzheimer Biomarkers (2022) (0)
WHITE MATTER NEUROINFLAMMATION IN PRECLINICAL ALZHEIMER DISEASE CAN BE QUANTIFIED BY DIFFUSION BASIS SPECTRUM IMAGING (2016) (0)
Anne M Fagan (2013) (0)
EXAMINING THE ASSOCIATION BETWEEN INTRAINDIVIDUAL MEANS AND STANDARD DEVIATIONS OF REACTION TIME AND PRECLINICAL ALZHEIMER DISEASE (2019) (0)
CSF tau phosphorylation at sites 217 and 181 are associated with preclinical and biphasic alterations in resting‐state functional connectivity in Autosomal Dominant AD (2022) (0)
Cerebrospinal fluid beta-amyloid 42, tau, ptau181 and resting state functional connectivity (2013) (0)
Change in cerebrospinal fluid tau microtubule binding region detects symptom onset, cognitive decline, tangles, and atrophy in Dominantly Inherited Alzheimer's Disease. (2023) (0)
Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer's disease. (2023) (0)
Increased cognitive effort costs in healthy aging and preclinical Alzheimer's disease. (2023) (0)
Biomarker clustering in autosomal dominant Alzheimer's disease (2022) (0)
Longitudinal cerebrospinal fluid phosphorylated tau181 and total tau do not reflect tau PET retention in dominantly inherited Alzheimer disease (2022) (0)
Baseline White Matter Neuroinflammation Predicts Cognitive Decline in Alzheimer Disease (2022) (0)
DEVELOPMENT OF AN INDICATOR CELL ASSAY FOR BLOOD-BASED DIAGNOSIS OF ALZHEIMER’S DISEASE (2019) (0)
P1-149 CSF VILIP-1 AND YKL-40, NOVEL CANDIDATE BIOMARKERS TO DIAGNOSE, PREDICT, AND MONITOR ALZHEIMER’S DISEASE THE (2014) (0)
EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: RESULTS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK (2017) (0)
Are early atrophy patterns in autosomal dominant familial Alzheimer's disease gene-dependent? (2013) (0)
Diagnostic value of plasma P‐tau217 in frontotemporal dementia spectrum disorders (2021) (0)
P3-088: Identification of potential biomarkers for Alzheimer's disease in cerebrospinal fluid using two-dimensional difference gel electrophoresis and tandem mass spectrometry: A multi-institutional collaborative study (2008) (0)
MARKERS IN BLOOD AND SPINAL FLUID , AND A NEW IMAGING AGENT , SHOW PROMISE FOR EARLY DETECTION OF ALZHEIMER (2008) (0)
Midlife changes in Alzheimer's biomarkers may predict dementia (2020) (0)
EFFECT OF SIMVASTATIN ON CSF ALZHEIMER’S DISEASE BIOMARKERS IN COGNITIVELY NORMAL ADULTS (2017) (0)
CSF tau phosphorylation at sites 217 and 205 mediate the relationship between PET amyloid and downstream AD markers (2022) (0)
SIMULTANEOUS QUANTIFICATION OF WHITE MATTER ABNORMALITIES AND VASOGENIC EDEMA IN EARLY ALZHEIMER'S DISEASE (2016) (0)
DIAGNOSTIC GROUPS TOWARDS P1-265 RATES OF PROGRESSION BETWEEN ALZHEIMER’S DISEASE: COMPARISON BETWEEN COHORT STUDIES (2017) (0)
CSF A β 42 Moderates the Relationship Between Brain Functional Network Dynamics and Cognitive Intra-Individual Variability (2021) (0)
Novel fluid biomarkers for brain amyloid and dementia risk in presymptomatic Alzheimer disease (2015) (0)
Discovery and validation of autosomal dominant Alzheimer’s disease mutations (2018) (0)
Neurogranin, a CSF biomarker for synaptic loss, predicts decline to dementia due to Alzheimer's disease (2015) (0)
CEREBROSPINAL FLUID ENDOPHENOTYPES PROVIDE INSIGHT INTO BIOLOGY UNDERLYING ALZHEIMER'S DISEASE (2017) (0)
Resilience and Reserve mechanisms underlying clinical‐cognitive progression in Dominant Inherited Alzheimer’s Disease. (2022) (0)
Early pathological changes due to Alzheimer's disease are detected by graph theoretical measures of functional connectivity (2013) (0)
Cross-sectional and longitudinal comparisons of biomarkers and cognition among asymptomatic middle-aged individuals with a parental history of either autosomal dominant or late-onset Alzheimer's disease. (2023) (0)
SYNERGISTIC AND MEDIATIONAL EFFECTS OF ALZHEIMER'S DISEASE BIOMARKERS ON A COGNITIVE MEASURE (2014) (0)
CROSS-SECTIONAL AND LONGITUDINAL RELATIONSHIPS AMONG BIOMARKERS FOR DOMINANTLY INHERITED ALZHEIMER’S DISEASE AND ITS COMPARISON WITH SPORADIC AD (2018) (0)
Modeling brain‐predicted age from functional connectivity in early‐stage and preclinical Alzheimer disease (2021) (0)
UTILITY OF PERFUSION PET MODELS AS MEASURE OF NEURODEGENERATION IN AN AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE POPULATION: REPORT FROM THE DIAN STUDY (2017) (0)
Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer’s disease (2018) (0)
NEUROINFLAMMATION IN ALZHEIMER’S DISEASE: TNF-α IS ASSOCIATED WITH ALTERED FUNCTIONAL CONNECTIVITY AMONG REWARD NETWORKS (2018) (0)
Data from: High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis (2019) (0)
Comparison of amyloid accumulation between Down syndrome and autosomal‐dominant Alzheimer disease (2022) (0)
Proteomic Clusters Underlie Heterogeneity in Preclinical AD Progression (2022) (0)
WHITE MATTER NEUROINFLAMMATION IN PRECLINICAL ALZHEIMER DISEASE CAN BE QUANTIFIED BY DIFFUSION BASIS SPECTRUM IMAGING (2016) (0)
Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease (2019) (0)
Neurofilament light is a non‐specific marker of aging and white matter integrity (2020) (0)
Cerebrospinal fluid beta-amyloid 42, tau, phosphorylated tau 181, and resting state functional connectivity (2013) (0)
Castellano 2011 Sci Transl Med-1 (2015) (0)
QUANTIFICATION OF WHITE MATTER CELLULARITY IN PRECLINICAL AND EARLY SYMPTOMATIC ALZHEIMER DISEASE USING NEURO-IMMNUE IMAGING (2018) (0)
DIAN-TU ADAPTIVE PREVENTION TRIAL LAUNCH AND BASELINE DATA (2018) (0)
Comparing neuroimaging and cerebrospinal fluid markers of amyloid, tau, and neurodegenerative biomarkers: implications for understanding the biology of the disease (2022) (0)
P3-026 Identification of biomarkers for Alzheimer's disease using proteomics approaches (2004) (0)
AV1451-PET UPTAKE AND CSF BIOMARKERS IN A HETEROGENEOUS CLINICAL SAMPLE: TWO SIDES OF THE SAME COIN? (2017) (0)
Clinical and quantitative comparison of amyloid PET tracers florbetapir and PiB (2014) (0)
P2-253 ANTEMORTEM CSF a-SYNUCLEIN PREDICTS TIME UNTIL DEATH IN AN AUTOPSY COHORT (2019) (0)
Cerebrospinal fluid biomarkers predict longitudinal decline in attentional control in the adult children study (2015) (0)
Longitudinal CSF changes in markers of neurodegeneration and utilization of these markers in predicting conversion from normal cognition to cognitive impairment (2012) (0)
Proteome Wide Association Studies of LRRK2 variants identify novel causal and druggable for Parkinsons disease (2023) (0)
CSF Biomarkers in Down Syndrome and Autosomal Dominant Alzheimer Disease (2021) (0)
PHOSPHORYLATION OF SPECIFIC TAU SITES IS ASSOCIATED WITH LOSS OF WHITE MATTER INTEGRITY IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE (2019) (0)
A STATISTICAL METHOD FOR DETERMINING BIOMARKER THRESHOLD FOR ALZHEIMER’S DISEASE (2018) (0)
TAU IMAGING RELATIONSHIPS WITH AMYLOID B IMAGING, CSF TAU/AB42, AND COGNITION IN ALZHEIMER’S DISEASE (2016) (0)
Global system segregation enhances reserve in normal aging and Alzheimer’s disease (2020) (0)
Elevated PiB precedes dementia in autosomal-dominant Alzheimer's disease: PiB, FDG and atrophy in the DIAN cohort (2012) (0)
Comparison of nia-aa preclinical Alzheimer's disease staging with CSF and neuroimaging biomarkers (2015) (0)
P2‐497: WITHDRAWN (2018) (0)
Early pathological changes due to Alzheimer's disease are detected by graph theoretical measures of functional connectivity (2013) (0)
THE CONTRIBUTION OF SEX-SPECIFIC ASSOCIATIONS IN GENETIC STUDIES OF ALZHEIMER’S DISEASE PATHOLOGY (2018) (0)
Lower body mass index is associated with greater Alzheimer pathology in asymptomatic individuals (2015) (0)
CSF tau predicts working memory and global cognitive decline in autosomal dominant Alzheimer’s disease (2015) (0)
Association between cerebrospinal fluid neurofilament light chain and markers of neurofibrillary pathophysiology: Findings from the Knight Alzheimer Disease Research Center (2020) (0)
Tau PET visual reads find sources of tau not explained by typical Alzheimer disease pathophysiology (2022) (0)
P3-065: Development of a solid phase extraction protocol for extracting peptides from cerebrospinal fluid in conjunction with tandem mass spectrometry to identify novel biomarkers for Alzheimer's disease (2008) (0)
O2-06-03: Late-onset Alzheimer's Disease–associated SNPS in TOMM40 and APOE have different effects on cerebrospinal fluid amyloid-beta levels (2008) (0)
REGIONAL PIB DEPOSITION AND CSF AB42 LEVELS SEVERAL YEARS PRIOR TO AMYLOID POSITIVITY (2014) (0)
P1-350: Effects of rare genetic variations in ABCA1 on apolipoprotein E levels in human cerebrospinal fluid (2006) (0)
P4-568 PROSPECTIVE ESCITALOPRAM DECREASES LONGITUDINAL CSFAb CONCENTRATION IN COGNITIVELY NORMAL ELDERLY SUBJECTS: A RANDOMIZED DOSE FINDING STUDY (2017) (0)
Limited Longitudinal Change in Self-reported Spatial Navigation Ability in Preclinical Alzheimer Disease (2021) (0)
Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease (2019) (0)
Baseline White Matter Neuroinflammation Predicts Cognitive Decline in Alzheimer Disease (2022) (0)
P2-141 Identification of CSF biomarkers for Alzheimer’s disease using proteomic approaches (2006) (0)
A voxel-based morphometry study of volumetric MRI in familial Alzheimer's disease (2012) (0)
CIRCULATING BRAIN-ENRICHED MICRORNAS AS BIOMARKERS FOR EARLY DETECTION AND DIFFERENTIAL DIAGNOSIS OF ALZHEIMER'S DISEASE (2016) (0)
DIAN OVERVIEW AND COHORT CHARACTERISTICS (2014) (0)
Predicting time to cognitive impairment using hippocampal volume (2013) (0)
QUANTIFYING CSF BIOFLUID BIOMARKERS OF NEURONAL INJURY, NEUROINFLAMMATION AND NEUROTRANSMISSION IN ANTIBODY-MEDIATED ENCEPHALITIS (2018) (0)
Correlation of the AD8: an Informant-Based Dementia Screening Tool with Amyloid Imaging and CSF Biomarkers of Alzheimer Disease (2010) (0)
EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: FINDINGS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK (2017) (0)
CRITICAL ANALYSIS OF BIOMARKER CUTOFFS IN ALZHEIMER DISEASE (2016) (0)
NOVEL CSF BIOMARKERS OF NEURONAL INJURY, SYNAPTIC DYSFUNCTION AND NEUROINFLAMMATION IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: VILIP-1, NEUROGRANIN, SNAP-25 AND YKL-40 IN THE DOMINANTLY INHERITED ALZHEIMER NETWORK (DIAN) (2018) (0)
CSF SPDGFRB, A MEASURE OF VASCULAR DYSFUNCTION, IS RELATED TO DISRUPTED FUNCTIONAL CONNECTIVITY AMONG BRAIN REGIONS ASSOCIATED WITH ALZHEIMER’S DISEASE (2018) (0)
ASSOCIATIONS BETWEEN VASCULAR RISK FACTORS AND AD BIOMARKERS IN COGNITIVELY NORMAL INDIVIDUALS (2017) (0)
GPS driving: a digital biomarker for preclinical Alzheimer disease (2021) (0)
BIOLOGICAL CORRELATES OF WHITE MATTER CHANGES IN AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE (2018) (0)
Demographic and psychosocial factors associated with the decision to learn mutation status in familial frontotemporal dementia and the impact of disclosure on mood (2021) (0)
Clinical value of CSF tau, p‐tau181, neurogranin and neurofilaments in familial frontotemporal lobar degeneration (2021) (0)
A methodology for normalizing fluid biomarker concentrations across reagent lots (2022) (0)
FDG metabolism in the DIAN study of autosomal dominant Alzheimer's disease (2012) (0)
EXAMINING THE INFLUENCE OF UNDETECTED ATN NEUROPATHOLOGY ON COGNITIVE AGING TRAJECTORIES (2006) (0)
Studying the natural history of frontotemporal lobar degeneration (FTLD): The ARTFL LEFFTDS longitudinal FTLD (ALLFTD) protocol (2020) (0)
CSF LEVELS OF STREM2 ARE ASSOCIATED WITH GREATER FRONTAL CORTICAL THICKNESS DURING ADVANCED DISEASE STAGES IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE (2016) (0)
Effect of BDNFVal66Met on disease markers in dominantly inherited AD (2018) (0)
ANTEMORTEM CSF α-SYNUCLEIN PREDICTS TIME UNTIL DEATH IN AN AUTOPSY COHORT (2019) (0)
Clinical, cognitive and biomarker profiles in dominantly‐inherited versus sporadic early‐onset Alzheimer’s disease (2021) (0)
A More Efficient Outcome for Alzheimer Disease Research: the Item Response Theory Based Score for the Clinical Dementia Rating (CDR®) (2022) (0)
RESTING-STATE FUNCTIONAL CONNECTIVITY ASSOCIATES WITH PATHOLOGICAL BIOMARKERS IN AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE (2018) (0)
WHAT GOES UP MUST COME DOWN: LONGITUDINAL DECLINE IN CEREBROSPINAL FLUID TAU PEPTIDES IS ASSOCIATED WITH PROGRESSIVE CORTICAL ATROPHY (2018) (0)
CROSS-SECTIONAL AND LONGITUDINAL COMPARISONS OF COGNITION AND BIOMARKERS AMONG COGNITIVELY NORMAL INDIVIDUALS AGED 42 TO 65 YEARS WITH A FAMILY HISTORY OF EITHER AUTOSOMAL DOMINANT AD (ADAD) OR LATE-ONSET AD (LOAD) (2017) (0)
O3-01-07 Relationship between in vivo amyloid imaging with 11C-PIB and CSF Aβ42 (2006) (0)
CSF BIOMARKERS IN DOWN SYNDROME (2019) (0)
APOE ε4 genotype, amyloid-β, and sex interact to predict tau in regions of high APOE mRNA expression (2022) (0)
O1-10-03 AN ACTIVE ANTI-AB40 VACCINE (ABVAC40) PROVED TO BE SAFE AND IMMUNOGENIC IN THE PHASE I CLINICAL TRIAL (2019) (0)
Higher systolic blood pressure in early-mid adulthood is associated with poorer cognitive performance in those with a dominantly inherited Alzheimer's disease mutation but not in non-carriers. Results from the DIAN study. (2023) (0)
Axonal damage and astrocytosis are biological correlates of grey matter network integrity loss: a cohort study in autosomal dominant Alzheimer disease (2023) (0)
P3-047 Probing for antecedent biomarkers of Alzheimer's disease through analysis of cerebrospinal fluid from middle-aged individuals (2004) (0)
LONGITUDINAL AMYLOID DEPOSITION AND HIPPOCAMPAL VOLUME IN SUSPECTED NON-ALZHEIMER PATHOPHYSIOLOGY AND PRECLINICAL ALZHEIMER'S DISEASE (2016) (0)
Increased cost of cognitive effort in preclinical Alzheimer’s disease (2021) (0)
Correlation of the AD8, an informant-based dementia screening tool, with amyloid imaging and CSF biomarkers of Alzheimer disease (2010) (0)
Longitudinal changes in cerebrospinal fluid biomarkers of Alzheimer's disease during middle-age in cognitively normal individuals with a positive family history (2012) (0)
Cognitive, neuropsychiatric and imaging comparisons between early‐onset and late‐onset Alzheimer’s disease participants from LEADS and ADNI3 (2021) (0)
Podium Presentations: Thursday, July 23, 2015 P326 O5-05-03 NEUROGRANIN, A CSF BIOMARKER FOR SYNAPTIC LOSS, PREDICTS DECLINE TO DEMENTIA DUE TO ALZHEIMER’S DISEASE (2015) (0)
Orderings of biomarker changes for Alzheimer disease in cognitively normal individuals from 18 to 101 years of age (2020) (0)
Statistical estimation and comparison of group-specific bivariate correlation coefficients in family-type clustered studies. (2022) (0)
CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease (2023) (0)
P2-016: Cortical binding of Pittsburgh compound B, an endophenotype for genetic studies of Alzheimer's disease (2008) (0)
IC-P-178 OCCUPATIONAL COMPLEXITY, COGNITIVE RESERVE, ANDWHITE MATTER HYPERINTENSITIES: FINDINGS FROM THE WISCONSIN REGISTRY FOR ALZHEIMER’S PREVENTION (2019) (0)
IMAGING MARKER OF NEUROINFLAMMATION PREDICTS DISEASE PROGRESSION IN ALZHEIMER DISEASE (2016) (0)
System in Alzheimer Disease Lysosomal - Proteasome System and the Autophagic - The Ubiquitin (2012) (0)
Progressive white matter injury in autosomal dominant Alzheimer’s disease is strongly associated with cerebral microbleeds and neurodegeneration (2022) (0)
P4-299 PHOSPHORYLATION OF SPECIFIC TAU SITES IS ASSOCIATEDWITH LOSS OF WHITE MATTER INTEGRITY IN AUTOSOMAL DOMINANTALZHEIMER DISEASE (2019) (0)
P2-202 URT: A new diagnostic approach for the early diagnosis of the Alzheimer’s disease (2006) (0)
YEARS TO PARENTAL SYMPTOM ONSET PREDICTS AMYLOID BURDEN IN HEALTHY ELDERLY WITH A PARENTAL HISTORY OF SPORADIC ALZHEIMER’S DISEASE (2017) (0)
AD‐causing variants that affect PSEN1 transmembrane domains are associated with faster neurodegeneration and cognitive decline compared to those affecting cytoplasmic domains. (2022) (0)
Longitudinal cascades of Alzheimer disease biomarkers across the entire adult lifespan among cognitively normal adults (2021) (0)
AV1451-PET UPTAKE AND CSF BIOMARKERS IN A HETEROGENEOUS CLINICAL SAMPLE: TWO SIDES OF THE SAME COIN? (2017) (0)
Evaluation of pre-analytical and analytical factors that contribute to variability in CSF biomarker levels (2013) (0)
Plasma levels of an N‐terminal tau fragment predict core AD and neurodegenerative biomarkers in autosomal dominant Alzheimer’s disease: Findings from DIAN (2022) (0)
The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer’s disease (2018) (0)
RELATING PET AND CSF MEASURE OF TAU PATHOLOGY (2016) (0)
Accuracy of Clinical Diagnosis of Dementia of the Alzheimer Type: Impact of Longitudinal Follow-up and Inclusion of CSF Biomarkers (2010) (0)
Higher amyloid correlates to greater loneliness during the COVID-19 pandemic (2022) (0)
JAMA Paper supplement (2015) (0)
CONCORDANCE BETWEEN CSF AD BIOMARKERS MEASURED BY THE AUTOMATED ELECSYS ASSAY AND IN VIVO AMYLOID IMAGING (2017) (0)
Gearing up for the future: Exploring facilitators and barriers to inform clinical trial design in frontotemporal lobar degeneration (2021) (0)
VALIDATING NON-AMYLOID, NON-TAU CSF BIOMARKERS FOR ALZHEIMER'S DISEASE IN THE PRE-SYMPTOMATIC, MCI, AND DEMENTIA STAGES: A MULTI-CENTER STUDY (2017) (0)
P3-102: Correlating hippocampal structure and CSF proteins in early dementia of the Alzheimer type (2008) (0)
β Peptide Clearance (2011) (0)
Comparing Tau PET Visual Interpretation with Tau PET Quantification, Cerebrospinal Fluid Biomarkers, and Longitudinal Clinical Assessment. (2023) (0)
ASSOCIATEDWITH A SPECIFIC PATTERN OF CEREBRALWHITE MATTER INJURY IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT ENROLLED TO THE ADNI STUDY (2015) (0)
Neuropsychological determinants of stage 3 of preclinical Alzheimer disease (2015) (0)
Dissociating volume and intensity differences in familial Alzheimer's disease (2013) (0)
CRITICAL ANALYSIS OF BIOMARKER CUTOFFS IN ALZHEIMER'S DISEASE (2016) (0)
Erratum: CSF biomarker variability in the Alzheimer's Association quality control program (Alzheimer's and Dementia (2013) 9 (251-261)) (2015) (0)
Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40 (2023) (0)
DEPRESSION AND ALZHEIMER DISEASE BIOMARKERS PREDICT DRIVING DECLINE (2018) (0)
The location of PSEN1 pathogenic variants in transmembrane vs. cytoplasmic domains may alter neurodegenerative and cognitive trajectories: Findings from the DIAN study (2021) (0)
Erratum: Reduced non-rapid eye movement sleep is associated with tau pathology in early Alzheimer's disease (Science Translational Medicine DOI: 10.1126/scitranslmed.aau6550) (2020) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Anne-marie C. Fagan?

Anne-marie C. Fagan is affiliated with the following schools:

Boston University
Emory University
Murdoch University